Dabigatran etexilate mesylate, the active ingredient in Pradaxa, is protected by a series of patents. These patents cover various aspects of the drug, including its composition, methods of use, and manufacturing processes [1]. DrugPatentWatch.com tracks these patents, providing detailed information on their status and expiry dates [2].
When does the main patent for Dabigatran expire?
The primary patent protecting dabigatran etexilate mesylate, U.S. Patent No. 5,948,776, was set to expire in 2018. However, patent term extensions and other related patents can extend market exclusivity for longer periods [1][2].
What are the other patents related to Dabigatran?
Beyond the primary composition of matter patent, numerous other patents exist for dabigatran. These include patents covering specific crystalline forms, polymorphic forms, and methods of manufacturing the drug substance and its formulations. For example, U.S. Patent No. 7,575,777 pertains to crystalline forms of dabigatran etexilate [1][2]. DrugPatentWatch.com lists and analyzes these secondary patents, which can impact the landscape of generic competition [2].
Can generic versions of Dabigatran be launched before patent expiry?
The launch of generic versions of dabigatran depends on the expiry of all relevant patents, including secondary patents and any periods of market exclusivity granted by regulatory bodies. Even after the primary patent expires, challenges to secondary patents or ongoing litigation can affect the timeline for generic entry [1][2].
How do patent challenges affect Dabigatran's market?
Patent challenges, such as Paragraph IV certifications in the United States, can accelerate the entry of generic competitors. If a generic manufacturer successfully challenges a patent, it can lead to earlier market entry and potentially lower drug prices. However, patent holders may pursue litigation to defend their intellectual property, leading to complex legal battles [1][2].
What is Dabigatran used for?
Dabigatran etexilate mesylate is an oral anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [3].
How does Dabigatran work?
Dabigatran is a direct thrombin inhibitor. By directly inhibiting thrombin, a key enzyme in the coagulation cascade, it prevents the formation of blood clots [3].
What are the risks associated with Dabigatran?
The main risk associated with dabigatran, like other anticoagulants, is bleeding. Patients may experience minor or major bleeding events, which can be serious [3].
How does Dabigatran compare to other anticoagulants?
Dabigatran belongs to a class of oral anticoagulants known as direct oral anticoagulants (DOACs). It competes with other DOACs such as rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), as well as older anticoagulants like warfarin [3]. Each anticoagulant has a different mechanism of action, dosing regimen, and risk profile.
What is the typical cost of Dabigatran?
The cost of dabigatran can vary significantly depending on insurance coverage, pharmacy pricing, and whether a generic version is available. Brand-name Pradaxa is generally more expensive than generic alternatives [4].
Who manufactures Dabigatran?
Dabigatran etexilate mesylate is manufactured by Boehringer Ingelheim [3].
Sources:
[1] https://drugpatentwatch.com/en/drug/dabigatran-etexilate-mesylate/patents
[2] https://drugpatentwatch.com/
[3] https://www.drugs.com/pradaxa.html
[4] https://www.drugs.com/price-guide/pradaxa